CD4 and myeloid sarcoma: More importantly, human CD4 T cells from healthy controls and MS patients were strongly susceptible to PPARγ-mediated suppression of Th17 differentiation, suggesting that PPARγ is a promising molecular target for specific immunointervention in Th17-mediated autoimmune diseases such as MS [52].